|
|
|
|
|
Background Information about Clinical Research
Glossary of clinical research terms
Listing of Newly Approved Drug Therapies
Oncology and Obstetrics/Gynecology
Notification Services
Sign-up for notification when this section is updated with new information. Anytime a new clinical trial is added, you will be notified via e-mail. Click here.
Latest News
Clinical Trials: Ovarian Cancer
New Jersey
- Belleville; Garden State Cancer Center
- A Phase I/II Radioimmunotherapy (RAIT) with High-Dose 90Y-Labeled Humanized MN-14 in Advanced Ovarian Cancer using Autologous Peripheral Blood Stem Cell Rescue (PBSCR) To Control Myelotoxicity
- Camden; The Cooper Health System
- Evaluation of Bovine Tracheal Cartilage in Recurrent Ovarian and Primary Peritoneal Carcinoma.
New York
- New York; Columbia-Presbyterian Medical Center
- Study of patients with persistent, refractory, or recurrent epithelial ovarian cancer
- New York; Columbia-Presbyterian Medical Center
- Study of patients with advanced epithelial ovarian cancer
- New York; Columbia-Presbyterian Medical Center
- A Phase II study of Docetaxel and Carboplatin for suboptimally debulked stage III or stage IV Ovarian Carcinoma and Fallopian Tube Carcinoma, or Primary Peritoneal Carcinoma
- Queens; Biomedical Research Alliance of New York, LLC
- Refractory and Resistant Stage III and IV Ovarian Cancer -- First-Line Therapy
- Queens; Biomedical Research Alliance of New York, LLC
- Stage III and IV Ovarian Cancer - First Line Therapy
Texas
- Houston; S. R. Burzynski Clinic
- Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Ovary
- Houston; S. R. Burzynski Clinic
- Phase II Study Of Antineoplastons A10 And AS2-1In Patients With Adenocarcinoma Of The Stomach
- Houston; S. R. Burzynski Clinic
- Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Uterine Cervix And/Or Vulva
Washington
- Seattle; University of Washington Medical Center
- Study of patients with advanced stage HER-2/neu expressing cancers
NIH
- National Institute of Health
- A Phase II Study of MGI-114 in Patients with Recurrent or Persistent Epithelial Ovarian Cancer
- National Institute of Health
- A Phase II Trial of Trastuzumab (Recombinant Humanized Anti-p185 HER2 Monoclonal Antibody) and Paclitaxel in Patients with HER2 Overexpressing Breast and Ovarian Tumors Who Have Relapsed or Progressive Disease Following Conventional Cytotoxic Chemotherapy
- National Institute of Health
- A Phase II Trial of Orally Administered CAI for Patients with Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- National Institute of Health
- Vaccine Therapy with Tumor Specific p53 Peptides in Adult Patients with Adenocarcinoma of the Ovary
- National Institute of Health
- A Pilot Study of Proteomic Evaluation of Epithelial Ovarian Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile Associated with Relapse
- National Institute of Health
- A Phase I Study of SU5416, an Antiangiogenesis Agent, in Combination with Carboplatin in Patients with Platinum-Refractory Ovarian Cancer
- National Institute of Health
- A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration
- National Institute of Health
- A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer
- National Institute of Health
- A Phase I Study of Weekly Gemcitabine Given in Combination with Infusional 5-Fluorouracil and Oral and Intravenous Calcium Leucovorin in Adult Cancer Patients
For the collection of research studies being conducted at the NIH Clinical Center.
Click here.
|
|
|
